A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer.
Hirotaka HasegawaKohei ShitaraShuji TakiguchiNoriaki TakiguchiSeiji ItoMitsugu KochiHidehito HorinouchiTakahiro KinoshitaTakaki YoshikawaKei MuroHiroyoshi NishikawaHideaki SunaYasuhiro KoderaPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2022)
Neoadjuvant nivolumab monotherapy is feasible with an acceptable safety profile and induces a MPR in certain patients with resectable GC. (Registration: clinicaltrials.jp, JapicCTI-183895).